M&A - RetinalGenix Technologies Inc.

Form Type: 10-K

Filing Date: 2025-03-31

Corporate Action: Acquisition

Type: Update

Accession Number: 000164117225001788

Filing Summary: RetinalGenix Technologies Inc. focuses on developing innovative ophthalmic devices to screen, monitor, diagnose, and treat sight-threatening ocular and systemic diseases. The company is nearing the launch of its RetinalCamTM device by Q4 2025 and continues to advance its products, including RTG-2023 for treatment of dry age-related macular degeneration and RTG-2024 for Alzheimer’s syndrome dementia. The company faced substantial financial challenges, including the need for approximately $6 million to support ongoing operations and product development. As of March 31, 2025, RetinalGenix's common stock outstanding was 18,522,295 shares. The firm also reported an acquisition of DNA/GPS Inc. on July 5, 2022, enhancing its capabilities in pharmacogenetic mapping for systemic and retinal diseases. RetinalGenix is relying on private placements for capital and has had limited revenue generation, raising concerns about its long-term viability without continued funding or successful product commercialization.

Document Link: View Document